Free Trial

Vaxcyte (PCVX) Stock Price, News & Analysis

Vaxcyte logo
$30.56 -3.13 (-9.29%)
Closing price 04:00 PM Eastern
Extended Trading
$31.35 +0.79 (+2.59%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vaxcyte Stock (NASDAQ:PCVX)

Key Stats

Today's Range
$30.01
$33.05
50-Day Range
$30.56
$92.13
52-Week Range
$30.02
$121.06
Volume
4.27 million shs
Average Volume
1.10 million shs
Market Capitalization
$3.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$136.50
Consensus Rating
Buy

Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Remove Ads

Vaxcyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

PCVX MarketRank™: 

Vaxcyte scored higher than 52% of companies evaluated by MarketBeat, and ranked 487th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vaxcyte has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vaxcyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vaxcyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vaxcyte is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vaxcyte is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vaxcyte has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Vaxcyte's valuation and earnings.
  • Percentage of Shares Shorted

    10.44% of the float of Vaxcyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Vaxcyte has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vaxcyte has recently increased by 2.27%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Vaxcyte does not currently pay a dividend.

  • Dividend Growth

    Vaxcyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.44% of the float of Vaxcyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Vaxcyte has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vaxcyte has recently increased by 2.27%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Vaxcyte has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 34 news articles for Vaxcyte this week, compared to 6 articles on an average week.
  • Search Interest

    10 people have searched for PCVX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,170,738.00 in company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Vaxcyte is held by insiders.

  • Percentage Held by Institutions

    96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vaxcyte's insider trading history.
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

PCVX Stock News Headlines

Bank of America Lowers Vaxcyte (NASDAQ:PCVX) Price Target to $137.00
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Mizuho Securities Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study
See More Headlines

PCVX Stock Analysis - Frequently Asked Questions

Vaxcyte's stock was trading at $81.86 at the beginning of the year. Since then, PCVX shares have decreased by 62.7% and is now trading at $30.56.
View the best growth stocks for 2025 here
.

Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14.

Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
2/25/2025
Today
4/03/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$136.50
High Stock Price Target
$163.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+353.4%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-402,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$13.04 per share
Price / Book
2.31

Miscellaneous

Free Float
120,773,000
Market Cap
$3.88 billion
Optionable
Optionable
Beta
1.02
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PCVX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners